Avanza Fonder AB Makes New Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

Avanza Fonder AB acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 759 shares of the company’s stock, valued at approximately $119,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Wilmington Savings Fund Society FSB bought a new stake in shares of Krystal Biotech in the 3rd quarter worth about $40,000. Values First Advisors Inc. acquired a new position in Krystal Biotech in the third quarter valued at about $53,000. GAMMA Investing LLC grew its stake in Krystal Biotech by 184.8% during the third quarter. GAMMA Investing LLC now owns 430 shares of the company’s stock worth $78,000 after buying an additional 279 shares during the last quarter. Huntington National Bank grew its stake in Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after buying an additional 283 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Krystal Biotech by 242.4% in the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after acquiring an additional 412 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

KRYS opened at $148.39 on Tuesday. The stock has a fifty day moving average of $170.98 and a 200-day moving average of $182.18. Krystal Biotech, Inc. has a fifty-two week low of $107.50 and a fifty-two week high of $219.34. The company has a market capitalization of $4.27 billion, a P/E ratio of 83.84 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. The company had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.67) EPS. On average, equities research analysts predict that Krystal Biotech, Inc. will post 3.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Chardan Capital restated a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a report on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday, December 18th. Finally, Citigroup boosted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $206.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).